<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4065">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471519</url>
  </required_header>
  <id_info>
    <org_study_id>BBIL/BBV152-A/2020</org_study_id>
    <secondary_id>Protocol No:BBIL/BBV152-A/2020</secondary_id>
    <nct_id>NCT04471519</nct_id>
  </id_info>
  <brief_title>Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers</brief_title>
  <acronym>BBV152</acronym>
  <official_title>An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bharat Biotech International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bharat Biotech International Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, Multi-Centre study to evaluate the safety, reactogenicity, tolerability, and&#xD;
      immunogenicity of three investigational vaccine groups and one placebo group in healthy&#xD;
      volunteers who receive two intramuscular doses of BBV152 vaccine formulations and placebo. A&#xD;
      total sample size of 755 healthy volunteers, with 375 and 380 volunteers in phase 1 and 2&#xD;
      studies, respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 study&#xD;
&#xD;
      The study is designed to evaluate the safety, reactogenicity, tolerability, and&#xD;
      immunogenicity of Four arms of healthy volunteers who receive two intramuscular doses of&#xD;
      BBV152 vaccine formulations or Placebo. A total no of 375 subjects will be enrolled in 4:1&#xD;
      ratio.&#xD;
&#xD;
      This study will be conducted in a dose escalatory manner with a two-dose regimen fourteen&#xD;
      days apart.&#xD;
&#xD;
      Phase 2 study&#xD;
&#xD;
      The study is designed to evaluate the safety, reactogenicity, tolerability, and&#xD;
      immunogenicity of two arms of healthy volunteers who will receive two intramuscular doses of&#xD;
      BBV152 vaccine formulations (BBV152-A &amp; BBV152-B) in a 1:1 ratio with dosage schedule on Day&#xD;
      0 and Day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Occurrence of adverse events and Serious Adverse events</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Evaluation of Neutralizing Antibody Titers</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Pre- and Post-vaccination immune response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Evaluation of Neutralizing Antibody Titers</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Pre- and Post-vaccination immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Occurrence of adverse events and Serious Adverse events</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">755</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>BBV152A - Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBV152B - Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBV152C - Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152C], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Phase I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mL of Placebo will be administered intramuscularly twice at Day 0 and Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBV152A - Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBV152B - Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BBV152A - Phase I</intervention_name>
    <description>0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14</description>
    <arm_group_label>BBV152A - Phase I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BBV152B - Phase I</intervention_name>
    <description>0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14</description>
    <arm_group_label>BBV152B - Phase I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BBV152C - Phase I</intervention_name>
    <description>0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14</description>
    <arm_group_label>BBV152C - Phase I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo - Phase I</intervention_name>
    <description>0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14</description>
    <arm_group_label>Placebo - Phase I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BBV152A - Phase II</intervention_name>
    <description>0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28</description>
    <arm_group_label>BBV152A - Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BBV152B - Phase II</intervention_name>
    <description>0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28</description>
    <arm_group_label>BBV152B - Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Ability to provide written informed consent.&#xD;
&#xD;
          2. Participants of either gender of age between ≥18 to ≤55 years.&#xD;
&#xD;
          3. Good general health as determined by the discretion of investigator (vital signs&#xD;
             (heart rate ≥60 to≤100 bpm; blood pressure systolic ≥90 mm Hg and &lt;140 mm Hg;&#xD;
             diastolic ≥ 60 mm Hg and &lt;90 mm Hg; oral temperature &lt;100.4ºF), medical history, and&#xD;
             physical examination).&#xD;
&#xD;
          4. Expressed interest and availability to fulfill the study requirements.&#xD;
&#xD;
          5. For a female participant of child-bearing potential, planning to avoid becoming&#xD;
             pregnant (use of an effective method of contraception or abstinence) from the time of&#xD;
             study enrolment until at least four weeks after the last vaccination&#xD;
&#xD;
          6. Male subjects of reproductive potential: Use of condoms to ensure effective&#xD;
             contraception with the female partner from first vaccination until 3 months after last&#xD;
             vaccination&#xD;
&#xD;
          7. Male subjects agree to refrain from sperm donation from the time of first vaccination&#xD;
             until 3 months after last vaccination&#xD;
&#xD;
          8. Participants must refrain from blood or plasma donation from the time of first&#xD;
             vaccination until 3 months after last vaccination&#xD;
&#xD;
          9. Agrees not to participate in another clinical trial at any time during the study&#xD;
             period.&#xD;
&#xD;
         10. Agrees to remain in the study area for the entire duration of the study.&#xD;
&#xD;
         11. Willing to allow storage and future use of biological samples for future research.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. History of any other COVID-19 investigational vaccination.&#xD;
&#xD;
          2. Unacceptable laboratory abnormality from screening (prior to first vaccination) or&#xD;
             safety testing, as listed below [Abnormal Complete Blood Count (CBC), Random blood&#xD;
             sugar level, Renal function test (serum urea and Creatinine), liver function tests,&#xD;
             urine analysis report, Positive serology for hepatitis C or HIV antibody or hepatitis&#xD;
             B surface antigen].&#xD;
&#xD;
             (Subjects will be informed if their results are positive for hepatitis C, HIV 1 &amp; 2&#xD;
             antibody or hepatitis B surface antigen (HBsAg) and will be referred to a primary care&#xD;
             provider for follow up of these abnormal laboratory tests.)&#xD;
&#xD;
          3. Confirmed SARS-CoV-2 at the time of screening using RT-PCR and ELISA method.&#xD;
&#xD;
          4. Health care workers.&#xD;
&#xD;
          5. For women, a positive serum pregnancy test (during screening within 45 days of&#xD;
             enrolment) or positive urine pregnancy test (within 24 hours of administering each&#xD;
             dose of vaccine).&#xD;
&#xD;
          6. Temperature &gt;38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an&#xD;
             upper respiratory infection or gastroenteritis within three days prior to each dose of&#xD;
             vaccine.&#xD;
&#xD;
          7. Medical problems as a result of alcohol or illicit drug use during the past 12 months.&#xD;
&#xD;
          8. Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before&#xD;
             enrollment or expects to receive an investigational agent during the study period.&#xD;
&#xD;
          9. Receipt of any licensed vaccine within four weeks before enrolment in this study.&#xD;
&#xD;
         10. Known sensitivity to any ingredient of the study vaccines, or a more severe allergic&#xD;
             reaction and history of allergies in the past.&#xD;
&#xD;
         11. Receipt of immunoglobulin or other blood products within the three months prior to&#xD;
             vaccination in this study.&#xD;
&#xD;
         12. Immunosuppression as a result of an underlying illness or treatment with&#xD;
             immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation&#xD;
             therapy within the preceding 36 months.&#xD;
&#xD;
         13. Long-term use (&gt; 2 weeks) of oral or parenteral steroids (glucocorticoids) or&#xD;
             high-dose inhaled steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent)&#xD;
             within the preceding six months (nasal and topical steroids are allowed).&#xD;
&#xD;
         14. Any history of hereditary angioedema or idiopathic angioedema.&#xD;
&#xD;
         15. Any history of anaphylaxis in relation to vaccination.&#xD;
&#xD;
         16. Any history of albumin-intolerance.&#xD;
&#xD;
         17. Pregnancy, lactation, or willingness/intention to become pregnant during the study.&#xD;
&#xD;
         18. History of any cancer.&#xD;
&#xD;
         19. History of psychiatric severe conditions likely to affect participation in the study.&#xD;
&#xD;
         20. A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or&#xD;
             prior history of significant bleeding or bruising following IM injections or&#xD;
             venepuncture.&#xD;
&#xD;
         21. Any other serious chronic illness requiring hospital specialist supervision.&#xD;
&#xD;
         22. Chronic respiratory diseases like severe acute respiratory syndrome (SARS), including&#xD;
             mild asthma.&#xD;
&#xD;
         23. Chronic cardiovascular disease, gastrointestinal disease, liver disease, renal&#xD;
             disease, endocrine disorder, and neurological illness&#xD;
&#xD;
         24. Morbidly obese (BMI≥35 kg/m2) or underweight (BMI ≤18 kg/m2).&#xD;
&#xD;
         25. Living in the same household of any COVID-19 positive person.&#xD;
&#xD;
         26. Any other condition that in the opinion of the investigator would jeopardize the&#xD;
             safety or rights of a volunteer participating in the trial or would render the subject&#xD;
             unable to comply with the protocol.&#xD;
&#xD;
             Re-Vaccination Exclusion Criteria&#xD;
&#xD;
         27. Pregnancy.&#xD;
&#xD;
         28. Anaphylactic reaction following administration of the investigational vaccine.&#xD;
&#xD;
         29. Virologically confirmed cases of COVID-19&#xD;
&#xD;
        Phase 2:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Ability to provide written informed consent (Audio video consent for vulnerable&#xD;
             subjects).&#xD;
&#xD;
          2. Participants of either gender of age between ≥12 to ≤ 65 years.&#xD;
&#xD;
          3. Good general health as determined by the discretion of investigator (vital signs&#xD;
             (heart rate ≥60 to≤100 bpm; blood pressure systolic ≥90 mm Hg and &lt;140 mm Hg;&#xD;
             diastolic ≥ 60 mm Hg and &lt;90 mm Hg; oral temperature &lt;100.4ºF), medical history, and&#xD;
             physical examination).&#xD;
&#xD;
          4. Expressed interest and availability to fulfill the study requirements.&#xD;
&#xD;
          5. For a female participant of child-bearing potential, avoid becoming pregnant (use of&#xD;
             an effective method of contraception or abstinence) from the time of study enrolment&#xD;
             until at least four weeks after the last vaccination and agrees not to participate in&#xD;
             another clinical trial at any time during the study period.&#xD;
&#xD;
          6. Male subjects of reproductive potential: Use of condoms to ensure effective&#xD;
             contraception with the female partner from first vaccination until 3 months after last&#xD;
             vaccination&#xD;
&#xD;
          7. Male subjects agree to refrain from sperm donation from the time of first vaccination&#xD;
             until 3 months after last vaccination&#xD;
&#xD;
          8. Participants must refrain from blood or plasma donation from the time of first&#xD;
             vaccination until 3 months after last vaccination.&#xD;
&#xD;
          9. Agrees to remain in the study area for the entire duration of the study.&#xD;
&#xD;
         10. Willing to allow storage and future use of biological samples for future research.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. History of any other COVID-19 investigational vaccination.&#xD;
&#xD;
          2. Confirmed SARS-CoV-2 at the time of screening using RT-PCR and ELISA method.&#xD;
&#xD;
          3. Health care workers.&#xD;
&#xD;
          4. Positive urine pregnancy test (within 24 hours of administering each dose of vaccine).&#xD;
&#xD;
          5. Temperature &gt; 38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an&#xD;
             upper respiratory infection or gastroenteritis within three days prior to each dose of&#xD;
             vaccine.&#xD;
&#xD;
          6. Medical problems as a result of alcohol or illicit drug use during the past 12 months.&#xD;
&#xD;
          7. Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before&#xD;
             enrolment or expects to receive an investigational agent during the study period.&#xD;
&#xD;
          8. Receipt of any licensed vaccine within four weeks before enrolment in this study.&#xD;
&#xD;
          9. Known sensitivity to any ingredient of the study vaccines, or a more severe allergic&#xD;
             reaction and history of allergies in the past.&#xD;
&#xD;
         10. Receipt of immunoglobulin or other blood products within the three months prior to&#xD;
             vaccination in this study.&#xD;
&#xD;
         11. Immunosuppression as a result of an underlying illness or treatment with&#xD;
             immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation&#xD;
             therapy within the preceding 36 months.&#xD;
&#xD;
         12. Long-term use (&gt; 2 weeks) of oral or parenteral steroids (glucocorticoids) or&#xD;
             high-dose inhaled steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent)&#xD;
             within the preceding six months (nasal and topical steroids are allowed).&#xD;
&#xD;
         13. Any history of hereditary angioedema or idiopathic angioedema.&#xD;
&#xD;
         14. Any history of anaphylaxis in relation to vaccination.&#xD;
&#xD;
         15. Any history of albumin-intolerance.&#xD;
&#xD;
         16. Pregnancy, lactation, or willingness/intention to become pregnant during the study.&#xD;
&#xD;
         17. History of any cancer.&#xD;
&#xD;
         18. History of psychiatric severe conditions likely to affect participation in the study.&#xD;
&#xD;
         19. A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or&#xD;
             prior history of significant bleeding or bruising following IM injections or&#xD;
             venepuncture.&#xD;
&#xD;
         20. Any other serious chronic illness requiring hospital specialist supervision.&#xD;
&#xD;
         21. Chronic respiratory diseases like severe acute respiratory syndrome (SARS), including&#xD;
             mild asthma.&#xD;
&#xD;
         22. Chronic cardiovascular disease, gastrointestinal disease, liver disease, renal&#xD;
             disease, endocrine disorder, and neurological illness&#xD;
&#xD;
         23. Morbidly obese (BMI≥35 kg/m2) or underweight (BMI ≤18 kg/m2).&#xD;
&#xD;
         24. Living in the same household of any COVID-19 positive person.&#xD;
&#xD;
         25. Any other condition that in the opinion of the investigator would jeopardize the&#xD;
             safety or rights of a volunteer participating in the trial or would render the subject&#xD;
             unable to comply with the protocol.&#xD;
&#xD;
             Re-Vaccination Exclusion Criteria&#xD;
&#xD;
         26. Pregnancy.&#xD;
&#xD;
         27. Anaphylactic reaction following administration of the investigational vaccine.&#xD;
&#xD;
         28. Virologically confirmed cases of COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Savita Verma, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PGIMS, Rohtak</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sanjay Kumar Rai, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Chandramani Singh, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, Patna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Ajeeth Pratap Singh, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rana Hospital and Trauma Centre, Gorakhpur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Satyajit Mohapatra, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SRM Hospital and Research Centre, Chennai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Prabhakar Reddy, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nizams Institute of Medical Sciences, Hyderabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Venkata Rao, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMS &amp; SUM Hospital, Orissa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Jitendra Kushwaha, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prakhar Hospital, Kanpur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sagar Vivek Redkar, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redkar Hospital and Research Center, Goa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Amit Bhate, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeevan Rekha Hospital, Belguam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Chadrashekar Gillukar, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gillukar Multispeciality Hospital, Nagpur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Vasudev R, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King George Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>560037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <zip>801507</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pt BD SHARMA,PGIMS/UHS</name>
      <address>
        <city>Rohtak</city>
        <state>Haryana</state>
        <zip>124001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeevan Rekha Hospital</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>590019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gillukar Multispeciality Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharastra</state>
        <zip>440009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Delhi</city>
        <state>New Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Sciences and SUM Hospital</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>751003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRM Hospital &amp; Research center</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>603211</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rana Hospital and Trauma Center</name>
      <address>
        <city>Gorakhpur</city>
        <state>Uttar Pradesh</state>
        <zip>273013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prakhar Hospital</name>
      <address>
        <city>Kanpur</city>
        <state>Uttar Pradesh</state>
        <zip>208002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redkar Hospital and Research Centre</name>
      <address>
        <city>Goa</city>
        <zip>403513</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 11, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BBV152</keyword>
  <keyword>COVID-19 vaccine</keyword>
  <keyword>inactivated vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

